These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 8388579

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate.
    Allersma DP, Smid WM, van der Does JA, van der Meer J, Briët E.
    Thromb Haemost; 1996 Feb; 75(2):261-6. PubMed ID: 8815573
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of a monoclonal purified factor VIII concentrate: 5-year follow-up in previously treated HIV-negative haemophiliacs.
    Smid WM, van der Meer J, Halie MR.
    Haemostasis; 1995 Feb; 25(5):229-36. PubMed ID: 7489961
    [Abstract] [Full Text] [Related]

  • 4. High versus ultra-high purity factor VIII concentrate therapy: prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs.
    Varon D, Schulman S, Dardik R, Barzilai A, Bashari D, Martinowitz U.
    Thromb Haemost; 1994 Sep; 72(3):359-62. PubMed ID: 7855784
    [Abstract] [Full Text] [Related]

  • 5. Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate.
    Mannucci PM, Gringeri A, de Biasi R, Baudo F, Morfini M, Ciavarella N.
    Thromb Haemost; 1992 Mar 02; 67(3):310-3. PubMed ID: 1353642
    [Abstract] [Full Text] [Related]

  • 6. T-lymphocyte subpopulations in patients with classic hemophilia treated with cryoprecipitate and lyophilized concentrates.
    Menitove JE, Aster RH, Casper JT, Lauer SJ, Gottschall JL, Williams JE, Gill JC, Wheeler DV, Piaskowski V, Kirchner P, Montgomery RR.
    N Engl J Med; 1983 Jan 13; 308(2):83-6. PubMed ID: 6401196
    [No Abstract] [Full Text] [Related]

  • 7. Immunological alterations in haemophiliacs treated with lyophilized Factor VIII cryoprecipitate from volunteer donors.
    Ceuppens JL, Vermylen J, Colaert J, Desmyter J, Gautama K, Stevens E, The AL, Vanham G, Vermylen C, Verstraete M.
    Thromb Haemost; 1984 Apr 30; 51(2):207-11. PubMed ID: 6429883
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Changes in T4/T8 ratio over a ten years period related to the factor VIII concentrates used in a group of HIV negative haemophiliacs.
    Smid WM, van der Meer J, Halie MR.
    Thromb Haemost; 1995 Mar 30; 73(3):552-3. PubMed ID: 7667844
    [No Abstract] [Full Text] [Related]

  • 12. CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients.
    Sabin C, Pasi J, Phillips A, Elford J, Janossy G, Lee C.
    Thromb Haemost; 1994 Aug 30; 72(2):214-7. PubMed ID: 7831654
    [Abstract] [Full Text] [Related]

  • 13. Lymphocyte subset ratios and factor VIII usage in haemophilia.
    Beddall AC, Al-Rubei K, Williams MD, Hill FG.
    Arch Dis Child; 1985 Jun 30; 60(6):530-6. PubMed ID: 3925894
    [Abstract] [Full Text] [Related]

  • 14. HIV antibody status and immunological abnormalities in Polish haemophiliacs.
    Lopaciuk S, Kacperska E, Gloskowska-Moraczewska Z, Maslanka K, Uhrynowska M, Kraj M, Seyfried H.
    Thromb Haemost; 1987 Feb 03; 57(1):41-3. PubMed ID: 3495899
    [Abstract] [Full Text] [Related]

  • 15. Immunological status and HIV antibodies in patients with haemophilia--a longitudinal study.
    Fuchs D, Hausen A, Reibnegger G, Werner ER, Vinazzer H, Dierich MP, Wachter H.
    Wien Klin Wochenschr; 1988 Aug 05; 100(15):505-9. PubMed ID: 3140497
    [Abstract] [Full Text] [Related]

  • 16. One year follow-up study of T-cell subsets and incidence of seropositivity for HTLV-I and HTLV-III antibodies in patients treated "on demand" or sporadically with clotting concentrates.
    Rodeghiero F, Castaman GC, Chisesi T, De Rossi A, Dalla Gassa O, Del Mistro A, Dini E, Castronovo S, Pornaro E, Chieco-Bianchi L.
    Thromb Haemost; 1985 Oct 30; 54(3):665-8. PubMed ID: 3003954
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP, Posthouwer D, Fischer K, van den Berg HM.
    Haemophilia; 2007 Nov 30; 13(6):697-700. PubMed ID: 17877729
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [HIV infection and immunity disorders in patients with hemophilia].
    Gotić M, Rolović Z, Brkić S, Vucković S, Bujko M, Lilić D, Dujić A.
    Srp Arh Celok Lek; 1989 Nov 30; 117(11-12):737-50. PubMed ID: 2490991
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.